NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Saved in:
| Title: | NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. |
|---|---|
| Authors: | Lee, Eudocia Q.1 (AUTHOR) eqlee@partners.org, Zhang, Peixin2 (AUTHOR), Wen, Patrick Y.1 (AUTHOR), Gerstner, Elizabeth R.3 (AUTHOR), Reardon, David A.1 (AUTHOR), Aldape, Kenneth D.4 (AUTHOR), deGroot, John F.5 (AUTHOR), Pan, Edward6 (AUTHOR), Raizer, Jeffrey J.7 (AUTHOR), Kim, Lyndon J.8 (AUTHOR), Chmura, Steven J.9 (AUTHOR), Robins, H. Ian10 (AUTHOR), Connelly, Jennifer M.11 (AUTHOR), Battiste, James D.12 (AUTHOR), Villano, John L.13 (AUTHOR), Wagle, Naveed14 (AUTHOR), Merrell, Ryan T.15 (AUTHOR), Wendland, Merideth M.16 (AUTHOR), Mehta, Minesh P.17 (AUTHOR) |
| Source: | Cancer (0008543X). Jun2020, Vol. 126 Issue 12, p2821-2828. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
